Application of next-generation sequencing to improve cancer management: A review of the clinical effectiveness and cost-effectiveness

O. Tan, R. Shrestha, M. Cunich, D. J. Schofield

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Uptake of next-generation sequencing (NGS) has increased dramatically due to significant cost reductions and broader community acceptance of NGS. To systematically review the evidence on both the clinical effectiveness and the cost-effectiveness of applying NGS to cancer care. A systematic search for full-length original research articles on the clinical effectiveness and cost-effectiveness of NGS in MEDLINE and EMBASE. Articles that focussed on cancer care and involved the application of NGS were included for the review of clinical effectiveness. For the cost-effectiveness review, we only included the articles with economic evaluations of NGS in cancer care. We report the rate of successfully detecting mutations from the clinical studies. The incremental cost-effectiveness ratio and sensitivity analysis outcomes are reported for the cost-effectiveness articles. Fifty-six articles reported that sequencing patient samples using targeted gene panels, and 83% of the successfully sequenced patients harboured at least 1 mutation. Only 6 studies reported on the cost-effectiveness of the application of NGS in cancer care. NGS is an effective tool for identifying mutation in cancer patients. However, more rigorous cost-effectiveness studies of NGS applied to cancer management are needed to determine whether NGS can improve patient outcomes cost-effectively.

LanguageEnglish
Pages533-544
Number of pages12
JournalClinical Genetics
Volume93
Issue number3
DOIs
Publication statusPublished - Mar 2018

Fingerprint

Cost-Benefit Analysis
Neoplasms
Mutation
Costs and Cost Analysis
MEDLINE
Research
Genes

Keywords

  • cancer
  • cost-effectiveness
  • economic evaluation
  • effectiveness
  • next-generation sequencing
  • quality of evidence

Cite this

@article{da2d889fea3c452f8ca5ec6277423616,
title = "Application of next-generation sequencing to improve cancer management: A review of the clinical effectiveness and cost-effectiveness",
abstract = "Uptake of next-generation sequencing (NGS) has increased dramatically due to significant cost reductions and broader community acceptance of NGS. To systematically review the evidence on both the clinical effectiveness and the cost-effectiveness of applying NGS to cancer care. A systematic search for full-length original research articles on the clinical effectiveness and cost-effectiveness of NGS in MEDLINE and EMBASE. Articles that focussed on cancer care and involved the application of NGS were included for the review of clinical effectiveness. For the cost-effectiveness review, we only included the articles with economic evaluations of NGS in cancer care. We report the rate of successfully detecting mutations from the clinical studies. The incremental cost-effectiveness ratio and sensitivity analysis outcomes are reported for the cost-effectiveness articles. Fifty-six articles reported that sequencing patient samples using targeted gene panels, and 83{\%} of the successfully sequenced patients harboured at least 1 mutation. Only 6 studies reported on the cost-effectiveness of the application of NGS in cancer care. NGS is an effective tool for identifying mutation in cancer patients. However, more rigorous cost-effectiveness studies of NGS applied to cancer management are needed to determine whether NGS can improve patient outcomes cost-effectively.",
keywords = "cancer, cost-effectiveness, economic evaluation, effectiveness, next-generation sequencing, quality of evidence",
author = "O. Tan and R. Shrestha and M. Cunich and Schofield, {D. J.}",
year = "2018",
month = "3",
doi = "10.1111/cge.13199",
language = "English",
volume = "93",
pages = "533--544",
journal = "Clinical Genetics",
issn = "0009-9163",
publisher = "Wiley-Blackwell, Wiley",
number = "3",

}

Application of next-generation sequencing to improve cancer management : A review of the clinical effectiveness and cost-effectiveness. / Tan, O.; Shrestha, R.; Cunich, M.; Schofield, D. J.

In: Clinical Genetics, Vol. 93, No. 3, 03.2018, p. 533-544.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Application of next-generation sequencing to improve cancer management

T2 - Clinical Genetics

AU - Tan, O.

AU - Shrestha, R.

AU - Cunich, M.

AU - Schofield, D. J.

PY - 2018/3

Y1 - 2018/3

N2 - Uptake of next-generation sequencing (NGS) has increased dramatically due to significant cost reductions and broader community acceptance of NGS. To systematically review the evidence on both the clinical effectiveness and the cost-effectiveness of applying NGS to cancer care. A systematic search for full-length original research articles on the clinical effectiveness and cost-effectiveness of NGS in MEDLINE and EMBASE. Articles that focussed on cancer care and involved the application of NGS were included for the review of clinical effectiveness. For the cost-effectiveness review, we only included the articles with economic evaluations of NGS in cancer care. We report the rate of successfully detecting mutations from the clinical studies. The incremental cost-effectiveness ratio and sensitivity analysis outcomes are reported for the cost-effectiveness articles. Fifty-six articles reported that sequencing patient samples using targeted gene panels, and 83% of the successfully sequenced patients harboured at least 1 mutation. Only 6 studies reported on the cost-effectiveness of the application of NGS in cancer care. NGS is an effective tool for identifying mutation in cancer patients. However, more rigorous cost-effectiveness studies of NGS applied to cancer management are needed to determine whether NGS can improve patient outcomes cost-effectively.

AB - Uptake of next-generation sequencing (NGS) has increased dramatically due to significant cost reductions and broader community acceptance of NGS. To systematically review the evidence on both the clinical effectiveness and the cost-effectiveness of applying NGS to cancer care. A systematic search for full-length original research articles on the clinical effectiveness and cost-effectiveness of NGS in MEDLINE and EMBASE. Articles that focussed on cancer care and involved the application of NGS were included for the review of clinical effectiveness. For the cost-effectiveness review, we only included the articles with economic evaluations of NGS in cancer care. We report the rate of successfully detecting mutations from the clinical studies. The incremental cost-effectiveness ratio and sensitivity analysis outcomes are reported for the cost-effectiveness articles. Fifty-six articles reported that sequencing patient samples using targeted gene panels, and 83% of the successfully sequenced patients harboured at least 1 mutation. Only 6 studies reported on the cost-effectiveness of the application of NGS in cancer care. NGS is an effective tool for identifying mutation in cancer patients. However, more rigorous cost-effectiveness studies of NGS applied to cancer management are needed to determine whether NGS can improve patient outcomes cost-effectively.

KW - cancer

KW - cost-effectiveness

KW - economic evaluation

KW - effectiveness

KW - next-generation sequencing

KW - quality of evidence

UR - http://www.scopus.com/inward/record.url?scp=85041657729&partnerID=8YFLogxK

U2 - 10.1111/cge.13199

DO - 10.1111/cge.13199

M3 - Article

VL - 93

SP - 533

EP - 544

JO - Clinical Genetics

JF - Clinical Genetics

SN - 0009-9163

IS - 3

ER -